Director at Stoke Therapeutics (STOK) sells 605 shares in plan trade

Rhea-AI Filing Summary

Stoke Therapeutics director Arthur A. Levin reported an open-market sale of 605 shares of Common Stock at $36.80 per share on March 13, 2026. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 12, 2025.

After this sale, Levin directly holds 4,237 shares of Stoke Therapeutics common stock and indirectly holds 17,979 shares through the Butler-Levin Revocable Trust, where he serves as trustee.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LEVIN ARTHUR A

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/13/2026		S(1)		605	D	$36.8	4,237	D
Common Stock								17,979	I	Arthur A. Levin, Ph.D., Trustee, Butler-Levin Revocable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2025.

	/s/ Jonathan Allan, Attorney-in-Fact	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Stoke Therapeutics (STOK) report for Arthur A. Levin?

Stoke Therapeutics director Arthur A. Levin reported selling 605 shares of Common Stock at $36.80 per share on March 13, 2026. This was an open-market transaction disclosed in a Form 4 filing.

Was Arthur A. Levin’s sale of Stoke Therapeutics (STOK) shares pre-planned?

Yes. The Form 4 notes the sale was executed under a Rule 10b5-1 trading plan adopted by Arthur A. Levin on November 12, 2025. Such plans are established in advance to systematically sell shares.

How many Stoke Therapeutics (STOK) shares did Arthur A. Levin sell and at what price?

Arthur A. Levin sold 605 shares of Stoke Therapeutics Common Stock at a price of $36.80 per share. The transaction occurred on March 13, 2026 as an open-market sale.

How many Stoke Therapeutics (STOK) shares does Arthur A. Levin own after the reported sale?

Following the reported sale, Arthur A. Levin directly owns 4,237 shares of Stoke Therapeutics. He also indirectly owns 17,979 shares through the Butler-Levin Revocable Trust, where he is trustee.

How are Arthur A. Levin’s indirect Stoke Therapeutics (STOK) holdings structured?

Levin’s indirect holdings are reported as 17,979 shares of Common Stock held through the Butler-Levin Revocable Trust. The filing identifies him as trustee of this trust, reflecting indirect ownership of those shares.